The Chelsea Clinic Expands into New Flagship at Ngee Ann City

Audio By Carbonatix

Part of SBC Medical Group, the clinic enhances patient experience and reinforces Singapore’s role as an aesthetic medicine hub

SINGAPORE - Media OutReach Newswire - 4 November 2025 - The Chelsea Clinic, a flagship brand of Aesthetic Healthcare Holdings ("AHH") and part of SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical"), has relocated to a significantly larger, purpose-built flagship facility at Ngee Ann City, one of Singapore's most prestigious landmarks. The expansion underscores SBC Medical's commitment to strengthening its presence in Asia while delivering a more seamless and elevated patient journey. The opening ceremony was graced by the presence of Mr. Toru Hotta, Deputy Chief of Mission, the Embassy of Japan in Singapore, who shared congratulatory remarks and joined the ribbon-cutting ceremony, adding a warm and memorable touch to the event.
The Chelsea Clinic Expands into New Flagship at Ngee Ann City
Founded in 1999 by Dr. Ewen Chee, The Chelsea Clinic has been a pioneer of aesthetic medicine in Singapore, introducing medically supervised aesthetic procedures for skin health and rejuvenation. Over the past two decades, the clinic has built a reputation as a trusted destination for both Singapore's local community and the sizeable Japanese expatriate population, as well as international patients seeking evidence-based care.
The new flagship brings together the medical clinic, spa, and corporate headquarters under one roof, offering a much larger and more integrated environment. With 16 rooms in total, including 12 clinic rooms and 4 spa rooms, it stands among Singapore's more expansive medical aesthetic clinics, thoughtfully designed to support privacy, comfort, and efficient patient care. Treatment rooms are named after Japanese cities, symbolizing the clinic's parentage under SBC Medical and its cross-cultural connection with Japan. In addition to increased space, the relocation enhances operational integration and patient services. Dedicated consultation rooms for each doctor and expanded waiting lounges create a more personalized and welcoming environment. Japanese-language support has also been strengthened, with multiple reservation channels including LINE (for Japanese speakers), WhatsApp, phone, and the clinic's bilingual website. A Japanese-speaking staff member is available to assist patients directly, ensuring clear communication and a seamless booking process.
From left: Yuya Yoshida, Director, CFO & COO of SBC Medical; Yoshiyuki Aikawa, CEO of SBC Medical; Mr. Toru Hotta, Deputy Chief of Mission, the Embassy of Japan in Singapore; and Dr. Ewen Chee, Founder and Medical Director of The Chelsea Clinic, and Lead Doctor for Asia Strategy at SBC Medical, at the ribbon-cutting ceremony.
Commenting on the relocation, Dr. Ewen Chee, Founder and Medical Director of The Chelsea Clinic and Lead Doctor for Asia Strategy at SBC Medical, said.
"Our relocation to Ngee Ann City reflects our commitment to providing a more elevated and seamless patient journey. By bringing our clinic, spa, and headquarters together in a larger, contemporary space, we can serve our long-standing patients and Singapore's Japanese community with even greater comfort, privacy and efficiency."
Hashtag: #SBCMedicalGroup #TheChelseaClinic #AestheticHealthcareHoldings #MedicalClinic #AestheticMedicine

The issuer is solely responsible for the content of this announcement.

About The Chelsea Clinic　　

Founded in 1999, The Chelsea Clinic is part of a network of medical aesthetic and wellness clinics in Singapore and a member of the SBC Medical Group, a medical and aesthetic services provider headquartered in Irvine, California, and listed on Nasdaq (Nasdaq: SBC).
With more than two decades of experience, The Chelsea Clinic provides evidence-based medical aesthetic services in a patient-centered environment. All treatments are doctor-supervised, with an emphasis on patient safety, privacy, and quality of care.
HP: https://chelseaclinic.com.sg/ja/home/
Instagram: https://www.instagram.com/thechelseaclinic/

About Aesthetic Healthcare Holdings (AHH)

AHH is a Singapore-based healthcare group operating aesthetic clinics, family medicine clinics, and quick-service facial aesthetics outlets. Its portfolio includes The Chelsea Clinic, Gangnam Laser Clinic, SkinGo!, and family clinics, serving a diverse patient base with accessible, high-quality care.

About SBC Medical Group Holdings Incorporated

SBC Medical Group Holdings Incorporated is a comprehensive medical group operating a wide range of franchise businesses across diverse medical fields, including advanced aesthetic medicine, dermatology, orthopedics, fertility treatment, dentistry, AGA (hair restoration), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose "Contributing to the well-being of people around the world through medical innovation," SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
For more information, visit https://sbc-holdings.com/
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," "targets" or "hopes" or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading "Risk Factors" and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), which are accessible on the SEC's website at www.sec.gov.